APDN: adnas.com Debt to Equity

APDN (Applied DNA Sciences Inc) - company brandmark

Applied DNA Sciences (APDN) specializes in resource authenticity verification via DNA tagging and the contract manufacturing of biocomponents. This chart of market quotes demonstrates a debt-to-equity ratio of 0.05. While patent protection creates a technological barrier, slow adoption of molecular tracking limits growth. Meanwhile, steady demand for healthcare offsets geopolitical risks associated with sanctions pressure on supplies.

APDN: adnas.com Total Debt to Capital 07/04/2022 - 10/07/2025
Core merchandise of Applied DNA Sciences

This ratio measures the degree of financial leverage by comparing total borrowed funds against net asset value to assess the stability of the balance sheet structure. By analyzing the total liabilities-to-equity chart, an investor can determine the deleveraging pace of Applied DNA Sciences (APDN), which is critical for a company whose demand within the US compliance control sector provides a stable foundation for business development.

Key competitors

TEM (tempus.com) - Total Debt to Capital|Debt to Equity Ratio QGEN (Qiagen NV)|Debt to Equity Ionis Pharma (IONS)|Repligen Inc. - Debt to Equity Ratio|Total Debt to Capital RNA (Avidity Biosciences)|Total Debt to Capital crisprtx.com CRSP|GeneDx - Total Debt to Capital|RARE - Total Debt to Capital|Beam Therapeutics Corp (BEAM) - Debt to Equity|Aggregate Debt to Equity SRPT (Sarepta Corp)|Debt to Equity Twist Bioscience|10xgenomics.com - Aggregate Debt to Equity|Debt to Equity Intellia Therapeutics, Inc. (NTLA)|Debt to Equity STOK (Stoke Therapeutics Inc)|Total Debt to Capital BLFS (BioLife Corp)|Total Debt to Capital Coefficient Wave Pharma (WVE)|Maze Therapeutics Inc - Total Debt to Capital|Debt to Capital sionnatx.com|PRME: Total Debt to Capital|Debt to Equity Ratio TSHA|Total Debt to Equity Ratio QURE|MGTX: All Debt to Shareholders' Equity Ratio|Total Debt to Capital RGNX|solidbio.com - Debt to Equity Ratio|Debt to Equity Ocugen OCGN|PACB: Debt to Equity Ratio|Benitec - Total Debt to Capital|DSGN - Total Debt to Capital|RCKT (Rocket Pharmaceuticals) - Total Debt to Equity Ratio|4dmoleculartherapeutics.com - All Debt to Shareholders' Equity Ratio|Debt to Equity Lexeo Therapeutics Inc.|Korro Bio, Inc (KRRO) - Total Debt to Capital Coefficient|Total Debt to Capital EDIT|Total Debt to Equity Ratio Silence Therapeutics Corp SLN|Total Debt to Capital PRQR (ProQR Therapeutics)|Total Debt to Capital Coefficient Codexis Inc (CDXS)|Sangamo Therapeutics, Inc. - Total Debt to Capital|Debt to Capital Nautilus Biotechnology|Metagenomi, Inc (MGX) - Debt to Equity|Debt to Equity Ratio DTIL|GBIO (Generation Bio Co) - Total Debt to Capital|Total Debt to Equity Ratio boundlessbio.com (BOLD)|Total Debt to Capital XCUR|IMNN - Debt to Capital|Debt to Equity Phio Pharmaceuticals Corp. PHIO|Total Debt to Capital Coefficient Mustang Bio Inc (MBIO)|TransCode - Total Debt to Capital|BNGO - Total Debt to Capital|bluebird bio (BLUE) - Debt to Equity|Aggregate Debt to Equity IPA (ImmunoPrecise Antibodies Ltd.)|OMGA (Omega) - Total Debt to Capital|Debt to Equity Ratio OMIC (Singular Genomics Corp)|Debt to Equity Regulus Therapeutics (RGLS)|syros.com - Debt to Equity Ratio|Total Debt to Capital TBIO (Telesis Bio)|TCON: Debt to Equity Ratio|UBX - Debt to Equity